InViragen Enlists Advanced BioScience Laboratories, Inc. for Manufacture of Master Virus Seed Stock for Plague Vaccine Development
Published: Feb 08, 2012
FORT COLLINS, Colo. & ROCKVILLE, Md.--(BUSINESS WIRE)--Inviragen, Inc. and Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies. Under this agreement, ABL will be responsible for the production and characterization of a master virus seed stock, a reservoir of virus produced under strict cGMP conditions, which will be used to support Inviragen’s development of a vaccine against plague. In addition, ABL will develop purified vaccine material to be used in future toxicology studies.